EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

Ling Han, Songmei Geng, Yangfeng Ding, Shifa Zhang, Xiaohua Wang, Fengming Hu, Jianguo Li, Chao Ci, Yayu Hu, Rixin Chen, Jianping Zhang, Xiaoyong Zhou und 13 weitere

Journal of the European Academy of Dermatology and Venereology · 28.07.2026

DOI: 10.1111/jdv.70643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 28.07.2026. Verfasst von Ling Han und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changzhou Hengbang Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tyrosine kinase 2 (TYK2), a key part of the inflammatory cascade responses, plays an integral role in the pathogenesis of psoriasis. Socrodeucitinib, an oral, TYK2 allosteric inhibitor, selectively inhibits TYK2 cytokine signalling pathways in psoriasis pathogenesis.

Objectives

To evaluate the efficacy and safety of socrodeucitinib in patients with moderate‐to‐severe plaque psoriasis.

Methods

In this phase 2, double‐blind, placebo‐controlled trial, 125 patients were randomly assigned (1:1:1) to receive socrodeucitinib at 6 mg, 12 mg or placebo orally, once daily, for 12 weeks. The primary endpoint was the proportion of patients with a 75% or greater reduction from the baseline in the Psoriasis Area and Severity Index (PASI) score at week 12.

Results

At week 12, significantly more patients treated with socrodeucitinib achieved a 75% reduction from baseline in PASI score compared with placebo (28.6% at 6 mg, 72.1% at 12 mg vs. 7.5% for placebo, p < 0.05 and p < 0.001, respectively). At the 12 mg dose, socrodeucitinib resulted in significantly higher response rates compared to placebo, with 46.5% of patients achieving PASI 90 ( p < 0.001) and 11.6% achieving PASI 100 ( p < 0.05). The treatment of socrodeucitinib also led to significantly higher proportions of patients achieving sPGA responses of 0 or 1 compared to placebo: 33.3% at 6 mg and 65.1% at 12 mg versus 10% for placebo ( p < 0.05 and p < 0.001, respectively). Most common adverse events included upper respiratory tract infection which demonstrated a certain dose dependency. Most treatment‐related adverse events were mild or moderate, and serious adverse events were infrequent, with no clinically meaningful abnormal trend in laboratory parameters.

Conclusions

Socrodeucitinib demonstrated significantly greater clearing of psoriasis plaques compared to placebo in patients with moderate‐to‐severe plaque psoriasis and illustrated a favourable safety and tolerability profile, warranting further investigation in longer‐duration and larger trials.

Schlagwörter

Stichwörter der Autor:innen

plaque psoriasispsoriasis area and severity indexsocrodeucitinibstatic physician global assessmenttyrosine kinase 2 inhibitor

Autor:innen und Institutionen

  • Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, China.
  • Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
  • Department of Dermatology, Northeast International Hospital, Shenyang, China.
  • Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China.
  • Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, China.

ORCID-Profile: Yan Zhou

Förderung

  • Changzhou Hengbang Pharmaceutical Co., Ltd.

Zitieren

APA

Han, L., Geng, S., Ding, Y., Zhang, S., Wang, X., Hu, F., Li, J., Ci, C., Hu, Y., Chen, R., Zhang, J., Zhou, X., Chen, A., Zhang, C., Lei, T., Feng, Y., Wang, Y., Meng, Z., Zhou, Y., …, & Xu, J. (2026). A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70643

Vancouver

Han L, Geng S, Ding Y, Zhang S, Wang X, Hu F, et al. A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70643

BibTeX
@article{Han2026,
  author = {Han, Ling and Geng, Songmei and Ding, Yangfeng and Zhang, Shifa and Wang, Xiaohua and Hu, Fengming and Li, Jianguo and Ci, Chao and Hu, Yayu and Chen, Rixin and Zhang, Jianping and Zhou, Xiaoyong and Chen, Aijun and Zhang, Chunlei and Lei, Tiechi and Feng, Yanyan and Wang, Yu and Meng, Zudong and Zhou, Yan and Ji, Mingkai and Liu, Wei and Wu, Yunting and Chen, Qianying and Wang, Siyi and Xu, Jinhua},
  title = {A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70643}
}
Kostenlos starten →